FDA issues Flonase, Nasonex letters

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase nasal spray, concerning detail aids used by reps for both brands.

The agency said the sales aids were false and misleading in making superiority claims over each other.

GSK stopped detailing for Flonase in 2006 when the drug went generic. The company is expected to take into account the FDA guidance to develop promotional material for its Flonase follow-on Veramyst.

Schering-Plough spokeswoman Mary-Fran Faraji told The Wall Street Journal the company had already replaced the Nasonex promotional materials. After receiving the FDA letter, the company told its sales reps not to use the old selling aids anymore. The company responded to FDA in writing and is working with the agency to resolve its concerns, she said.  

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?